Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome

Background—The combination of cardiac and renal disease driven by metabolic risk factors, referred to as cardiorenal metabolic syndrome (CRMS), is increasingly recognized as a critical pathological entity. The contribution of (micro)vascular injury to CRMS is considered to be substantial. However, mechanistic studies are hampered by lack of in vivo models that mimic the natural onset of the disease. Here, we evaluated the coronary and renal microvasculature during CRMS development in obese diabetic Zucker fatty/Spontaneously hypertensive heart failure F1 hybrid (ZSF1) rats. Methods and Results—Echocardiographic, urine, and blood evaluations were conducted in 3 groups (Wistar-Kyoto, lean ZSF1, and obese ZSF1) at 20 and 25 weeks of age. Immunohistological evaluation of renal and cardiac tissues was conducted at both time points. At 20 and 25 weeks, obese ZSF1 rats showed higher body weight, significant left ventricular hypertrophy, and impaired diastolic function compared with all other groups. Indices of systolic function did not differ between groups. Obese ZSF1 rats developed hyperproliferative vascular foci in the subendocardium, which lacked microvascular organization and were predilection sites of inflammation and fibrosis. In the kidney, obese ZSF1 animals showed regression of the peritubular and glomerular microvasculature, accompanied by tubulointerstitial damage, glomerulosclerosis, and proteinuria. Conclusions—The obese ZSF1 rat strain is a suitable in vivo model for CRMS, sharing characteristics with the human syndrome during the earliest onset of disease. In these rats, CRMS induces microvascular fibrotic responses in heart and kidneys, associated with functional impairment of both organs.

[1]  Rinaldo Bellomo,et al.  Cardiorenal syndrome. , 2008, Journal of the American College of Cardiology.

[2]  M. Verhaar,et al.  The complex mural cell: pericyte function in health and disease. , 2015, International journal of cardiology.

[3]  A. Leite-Moreira,et al.  Echocardiography and invasive hemodynamics during stress testing for diagnosis of heart failure with preserved ejection fraction: an experimental study. , 2015, American journal of physiology. Heart and circulatory physiology.

[4]  D. Cohen,et al.  Cardiovascular and Renal Effects of Weight Reduction in Obesity and the Metabolic Syndrome , 2015, Current Hypertension Reports.

[5]  W. Edwards,et al.  Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[6]  I. Komuro,et al.  Angiogenesis and Cardiac Hypertrophy: Maintenance of Cardiac Function and Causative Roles in Heart Failure , 2014, Circulation research.

[7]  W. Paulus,et al.  Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model , 2013, Circulation. Heart failure.

[8]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[9]  R. D. de Boer,et al.  Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. , 2013, European heart journal.

[10]  G. Fonarow,et al.  Cardiorenal syndrome: pathophysiology and potential targets for clinical management , 2013, Nature Reviews Nephrology.

[11]  W. Paulus,et al.  Abstract 17471: The Obese Zsf1 Rat as a New Model of Heart Failure with Preserved Ejection Fraction Accompanying the Metabolic Syndrome , 2012 .

[12]  R. Goldschmeding,et al.  Target organ cross talk in cardiorenal syndrome: animal models. , 2012, American journal of physiology. Renal physiology.

[13]  S. Umemura,et al.  Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. , 2012, Journal of the American College of Cardiology.

[14]  J. Bronzwaer,et al.  Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction , 2012, Circulation.

[15]  R. Goldschmeding,et al.  Subtotal nephrectomy plus coronary ligation leads to more pronounced damage in both organs than either nephrectomy or coronary ligation. , 2012, American journal of physiology. Heart and circulatory physiology.

[16]  S. Bastacky,et al.  Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. , 2011, The Journal of endocrinology.

[17]  C. Ronco,et al.  The Cardiorenal Syndrome , 2011, International journal of nephrology.

[18]  J. Lopes,et al.  Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad , 2011, Cardiology research and practice.

[19]  P. Steendijk,et al.  Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.

[20]  J. Sowers,et al.  The Role of Overweight and Obesity in the Cardiorenal Syndrome , 2011, Cardiorenal Medicine.

[21]  F. Ziyadeh,et al.  The cardiorenal syndrome in diabetes mellitus. , 2010, Diabetes research and clinical practice.

[22]  H. Katus,et al.  Uremia Aggravates Left Ventricular Remodeling after Myocardial Infarction , 2010, American Journal of Nephrology.

[23]  D. Hodge,et al.  Progression of preclinical diastolic dysfunction to the development of symptoms , 2010, Heart.

[24]  G. Bakris,et al.  Dysglycemia Predicts Cardiovascular and Kidney Disease in the Kidney Early Evaluation Program , 2010, Journal of clinical hypertension.

[25]  R. Henning,et al.  Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  M. Picken,et al.  Dynamic blood pressure load and nephropathy in the ZSF1 (fa/fa cp) model of type 2 diabetes. , 2007, American journal of physiology. Renal physiology.

[27]  Ali Ahmed,et al.  Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. , 2007, The American journal of cardiology.

[28]  F. Afshinnia,et al.  Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[30]  Jiang He,et al.  Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. , 2006, The American journal of medicine.

[31]  Ruoling Chen,et al.  Mild to moderate renal impairment is associated with increased left ventricular mass. , 2006, International journal of cardiology.

[32]  G. Chertow,et al.  Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  A. A. Aleksandrov,et al.  Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. , 2005, Diabetes research and clinical practice.

[34]  R. Henning,et al.  Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. , 2004, Journal of the American Society of Nephrology : JASN.

[35]  Samy I McFarlane,et al.  The relationship between hyperinsulinemia, hypertension and progressive renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[36]  P. Armstrong,et al.  Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.

[37]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[38]  C. O'connor,et al.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. , 2004, Journal of the American College of Cardiology.

[39]  C. Murry,et al.  Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. , 2003, The American journal of pathology.

[40]  Daniel W. Jones,et al.  Mechanisms of obesity-associated cardiovascular and renal disease. , 2002, The American journal of the medical sciences.

[41]  S. Bastacky,et al.  RENAL FUNCTION AND STRUCTURE IN DIABETIC, HYPERTENSIVE, OBESE ZDFxSHHF-HYBRID RATS , 2000, Renal failure.

[42]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.